U.S. MARKETS FOR PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY AND CORONARY STENTING PRODUCTS
192 Pages | 33 Exhibits | 2010 Analysis | Forecasts Through 2014
In the United States (U.S.), the single largest cause of death--and also the greatest cause of premature and permanent disability in the labor force--is coronary heart disease (CHD). Nearly 18 million adults age 20 or older in the U.S. suffer from CHD, which is responsible for more than 50% of all cardiovascular events in men and women younger than age 75, and for 1 out of every 6 deaths in the country. The morbidity and mortality rates associated with CHD continue to fuel the demand for percutaneous transluminal coronary angioplasty (PTCA) and coronary stenting products to treat patients who cannot be adequately managed with lifestyle changes or medical therapy.
Together, more than a million PTCA and coronary stenting procedures were performed in the U.S. in 2009, generating approximately $4.2 billion in corresponding product sales. It is expected that during the forecast period covered by this report, sales of PTCA and coronary stenting products will increase at a compound annual rate of 6.6%, reaching an estimated $5.8 billion in the year 2014.
This dynamic, new report from Medtech Insight includes analyses of products, current and forecast markets, competitors, and opportunities for suppliers of PTCA and coronary stenting products to the U.S.
Covered topics in this report include bare-metal and drug-eluting stent systems; conventional and drug-eluting balloon angioplasty procedures; conventional balloon angioplasty catheters; coronary heart disease and population statistics; coronary stenting procedures; drug-eluting balloon angioplasty catheters; guidewires; guiding catheters; inflation devices; introducers/sheaths; stent coatings and surfaces and anti-restenosis agents; stent configurations and materials; technological developments in coronary angioplasty and stenting; and vascular access site closure devices.
TABLE OF CONTENTS:
i. Percutaneous Transluminal Coronary Angioplasty Devices Market
ii. Coronary Stenting Systems Market
Exhibit ES-1: Percutaneous Transluminal Coronary Angioplasty/Coronary Stenting, Procedure Volumes Forecast, 2009-2014
Exhibit ES-2: Percutaneous Transluminal Coronary Angioplasty/Coronary Stenting Products, Market Forecast, 2009-2014
Exhibit ES-3: Percutaneous Transluminal Coronary Angioplasty Devices, Market Forecast, 2009-2014
Exhibit ES-4: Coronary Stents, Market Forecast, 2009-2014
1. CORONARY HEART DISEASE OVERVIEW
1.1 The Heart and Circulatory System
1.2 Selected Heart Diseases/Disorders
1.2.1 Coronary Heart Disease
22.214.171.124 Angina Pectoris
126.96.36.199 Myocardial Infarction
188.8.131.52 Systolic and Diastolic Pressures
1.2.3 Cardiac Dysrhythmia
184.108.40.206 Sick Sinus Syndrome
220.127.116.11 Heart Block
18.104.22.168 Atrial Fibrillation
22.214.171.124 Ventricular Fibrillation
126.96.36.199 Dilated Cardiomyopathy
188.8.131.52 Hypertrophic Cardiomyopathy
184.108.40.206 Restrictive Cardiomyopathy
1.2.5 Congenital Heart Defects
220.127.116.11 Ventricular Septal Defects
18.104.22.168 Atrial Septal Defects
22.214.171.124 Patent Ductus Arteriosus
1.2.6 Heart Failure
126.96.36.199 Disease Development
188.8.131.52 Ejection Fraction Reduction
184.108.40.206 Classification/Staging Systems
Exhibit 1-1: Cross-Section Diagram of the Heart
Exhibit 1-2: Cross-Section Diagram of the Heart Valves
Exhibit 1-3: Statistics for Selected Coronary Heart Disease Risk Factors
Exhibit 1-4: Standard Angina Pectoris Classification
Exhibit 1-5: Angina Pectoris, Selected Statistics
Exhibit 1-6: Myocardial Infarction, Selected Statistics
Exhibit 1-7: Percentage of Adults Who Have Been Told They Have High Blood Pressure, by State
Exhibit 1-8: Hypertension, Selected Statistics
Exhibit 1-9: Cardiac Dysrhythmia, Selected Statistics
Exhibit 1-10: Cardiomyopathy, Selected Statistics
Exhibit 1-11: Congenital Heart Defects, Selected Statistics
Exhibit 1-12: Summary, New York Heart Association Heart Failure Classification System
Exhibit 1-13: Summary, American College of Cardiology/American Heart Association Heart Failure Staging System
Exhibit 1-14: Heart Failure, Selected Statistics
2. PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY PRODUCTS MARKET
2.1 Percutaneous Transluminal Coronary Angioplasty
2.1.4 Adjunctive Anti-Clotting Drug Therapies
2.1.5 Conventional Angioplasty and Emerging Drug-Eluting Balloon Angioplasty
220.127.116.11 Balloon Angioplasty Catheters
18.104.22.168 Guiding Catheters
22.214.171.124 Inflation Devices
126.96.36.199 Vascular Access Site Closure Devices
2.1.7 Procedure Volumes Forecast
2.1.8 Market Forecast
Exhibit 2-1: 2010, Selected Conventional Percutaneous Transluminal Coronary Angioplasty Balloon Catheters
Exhibit 2-2: 2010, Selected Drug-Eluting Balloon Angioplasty Catheters
Exhibit 2-3: 2010, Selected Guiding Catheters
Exhibit 2-4: 2010, Selected Guidewires
Exhibit 2-5: 2010, Selected Inflation Devices
Exhibit 2-6: 2010, Selected Introducers/Sheaths
Exhibit 2-7: 2010, Selected Vascular Access Site Closure Devices
Exhibit 2-8: Percutaneous Transluminal Coronary Angioplasty/Coronary Stenting, Procedure Volumes Forecast, 2009-2014
Exhibit 2-9: Percutaneous Transluminal Coronary Angioplasty Devices, Market Forecast, 2009-2014
Exhibit 2-10: 2009, Percutaneous Transluminal Coronary Angioplasty Devices Market, Share by Supplier
3. CORONARY STENT SYSTEMS MARKET
3.1 Coronary Stenting with Bare-Metal and Drug-Eluting Stents
3.1.1 Stent Materials
188.8.131.52 Cobalt-Based Alloys
184.108.40.206 Stainless Steel
220.127.116.11 Bioabsorbable Polymers and Metal-Based Alloys
3.1.2 Stent Coatings/Surfaces and Anti-Restenosis Agents
3.1.3 Stent Delivery/Deployment
18.104.22.168 Left Main Coronary Artery Disease
22.214.171.124 Multivessel Coronary Artery Disease
126.96.36.199 Repeat Revascularization
188.8.131.52 Stent Thrombosis
184.108.40.206 Diabetes and Stenting
220.127.116.11 Stenting-Associated ST-Segment Elevation Myocardial Infarction
3.1.7 Procedure Volumes Forecast
3.1.8 Market Forecast
Exhibit 3-1: 2010, Selected Anti-Restenosis Agents
Exhibit 3-2: 2010, Selected Coronary Stents
Exhibit 3-3: Coronary Stenting, Procedure Volumes Forecast, 2009-2014
Exhibit 3-4: Coronary Stents, Market Forecast, 2009-2014
Exhibit 3-5: 2009, Coronary Stent Systems Market, Share by Supplier
4. COMPANY PROFILES1
4.1 Abbott Laboratories
4.2 Boston Scientific Corporation
4.3 B. Braun Melsungen AG
4.4 Cook Group, Inc.
4.5 Cordis Corporation/Johnson & Johnson
4.6 InSitu Technologies, Inc.
4.7 Medtronic, Inc.
4.8 Merit Medical Systems, Inc.
4.10 St. Jude Medical, Inc.
4.11 Terumo Medical Corporation/Terumo Corporation
4.12 Vascular Solutions, Inc.
APPENDIX: COMPANY LISTING
- Boston Scientific Corporation
- B. Braun Melsungen AG
- Cook Group, Inc.
- Cordis Corporation/Johnson & Johnson
- InSitu Technologies, Inc.
- Medtronic, Inc.
- Merit Medical Systems, Inc.
- St. Jude Medical, Inc.
- Terumo Medical Corporation/Terumo Corporation
- Vascular Solutions, Inc.